Two Sigma Investments LP Grows Stake in uniQure (NASDAQ:QURE)

Two Sigma Investments LP lifted its stake in uniQure (NASDAQ:QURE - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 878,884 shares of the biotechnology company's stock after purchasing an additional 73,988 shares during the quarter. Two Sigma Investments LP owned 1.80% of uniQure worth $15,521,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 969 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in uniQure in the 4th quarter worth approximately $437,000. Oppenheimer & Co. Inc. bought a new position in uniQure in the 4th quarter valued at approximately $320,000. Raymond James Financial Inc. purchased a new stake in uniQure during the 4th quarter valued at $1,951,000. Finally, Monaco Asset Management SAM purchased a new stake in uniQure during the 4th quarter valued at $2,414,000. Institutional investors own 78.83% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday. Finally, Wall Street Zen upgraded shares of uniQure to a "sell" rating in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.82.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares in the company, valued at $6,574,599.40. This represents a 1.14% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock worth $961,401. Corporate insiders own 4.74% of the company's stock.

uniQure Stock Down 1.7%

Shares of QURE stock opened at $15.23 on Friday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The stock has a market cap of $834.24 million, a P/E ratio of -3.07 and a beta of 0.10. The company has a 50 day simple moving average of $12.41 and a two-hundred day simple moving average of $12.54.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts expect that uniQure will post -3.75 earnings per share for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.